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Abstract Misfolding of the prion protein yields amyloidogenic
isoforms, and it shows exacerbating neuronal damage in neuro-
degenerative disorders including prion diseases. Pituitary ade-
nylate cyclase-activating polypeptide (PACAP) and vasoactive
intestinal peptide (VIP) potently stimulate neuritogenesis and
survival of neuronal cells in the central nervous system. Here,
we tested these neuropeptides on neurotoxicity in PC12 cells
induced by the prion protein fragment 106^126 [PrP (106^
126)]. Concomitant application of neuropeptide with PrP(106^
126) (5U1035 M) inhibited the delayed death of neuron-like
PC12 cells. In particular, PACAP27 inhibited the neurotoxicity
of PrP(106^126) at low concentrations (s 10315 M), charac-
terized by the deactivation of PrP(106^126)-stimulated caspase-
3. The neuroprotective e¡ect of PACAP27 was antagonized by
the selective PKA inhibitor, H89, or the MAP kinase inhibitor,
U0126. These results suggest that PACAP27 attenuates
PrP(106^126)-induced delayed neurotoxicity in PC12 cells by
activating both PKA and MAP kinases mediated by PAC1
receptor. 5 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Prion diseases are unusual fetal neurodegenerative disor-
ders, including Creutzfeldt^Jakob disease and Gerstmann^
Straussler^Scheinker syndrome in humans, scrapie in sheep
and goats, and spongiform encephalopathy in cattle [1]. These
diseases are characterized by the accumulation of large aggre-
gates of the prion protein (PrP) in both human and animal
brains. PrP tends to adopt a L-sheet conformation in bu¡ered
solutions, and aggregates into amyloid ¢brils that are partly
resistant to protease digestion [2]. The prion protein fragment
PrP(106^126), corresponding to a putative transmembrane re-
gion of cellular PrP, is believed to be one of the key regions
where conformational changes are initiated, leading to the
conversion of native cellular prion protein (PrPc) to scrapie
isoform of prion protein (PrPsc) [3]. This peptide shows a
remarkable conformational polymorphism, acquiring di¡erent
secondary structures in various environments, and it has been
shown to induce cell death in neurons likely via the pro-
grammed cell death pathway. The importance of the 106^
126 sequence of PrP makes it a useful model for the in vitro
study of prion-induced cell death. Although evidence is accu-
mulating for the hypothesis that in£ammatory components
such as cytokines and complement proteins play a signi¢cant
role in exacerbating neuronal damage in neurodegenerative
disorders including prion diseases [4], it is still unclear how
PrPsc accumulation gives rise to the profound neurodegenera-
tion characteristic of scrapie.
Pituitary adenylate cyclase-activating polypeptide (PACAP)
[5] and vasoactive intestinal peptide (VIP) [6] are two neuro-
peptides that perform a broad spectrum of biological func-
tions a¡ecting both natural and acquired immunity, primarily
as regulatory agents. There are two forms of mammal PA-
CAP, PACAP38 and a shorter peptide with the same N-ter-
minal 27 residue, PACAP27, and they have been shown to
have the same biological activity and receptor-binding activity
[7]. PACAP and VIP have been shown to act as survival
factors against ischemia and glutamate-induced neurotoxic-
ities [8], and in vitro studies have demonstrated that they
can stimulate neurite outgrowth [9].
These observations prompted us to investigate the e¡ect of
neuropeptides including PACAP and VIP on the PrP-induced
neurotoxicity using neuron-like PC12 cells, in which the ex-
pression of PACAP-speci¢c PAC1 receptor was con¢rmed
[10]. In addition, we evaluated how PACAP/VIP in£uence
the cytotoxicity level, characterized by caspase cascades and
protein kinase signaling pathways.
2. Materials and methods
2.1. Chemicals
The neuropeptides PACAP and VIP were synthesized by the solid-
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phase strategy employing optimal side-chain protection as reported
previously [11]. Human PrP(106^126) was purchased from American
Peptide Company (Sunnyvale, CA, USA). 4-[3-(2-Methoxy-4-nitro-
phenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate so-
dium salt (WST-8) was purchased from Dojindo (Kumamoto, Japan).
Dibutyryl-cAMP (db-cAMP), 12-O-tetradecanoyl-phorbol-13-acetate
(TPA), bis[amino [(2-aminophenyl)thio]methylene]butanedinitrile
(U0126) and N-(2-[p-bromocinnamylamino]ethyl)-5-isoquinolinesulfo-
namide (H-89) were purchased from Sigma (St. Louis, MO, USA).
Myristoyl-Gly-Arg-Arg-Asn-Ala-Ile-His-Asp-Ile (Myr-iPKC), acetyl-
Asp-Glu-Val-Asp-1-al (Ac-DEVD-CHO) and N-benzyloxycarbonyl-
Val-Ala-Asp(O-Me) £uoromethyl ketone (Z-VAD-FMK) were pur-
chased from Promega (Madison, WI, USA).
2.2. Cell cultures
Rat pheochromocytoma (PC12) cells were obtained from the RI-
KEN Cell Bank (Ibaraki, Japan). The PC12 cells were cultured in
Dulbecco’s modi¢ed Eagle’s medium (DMEM; Sigma) supplemented
with 5% (v/v) horse serum (Gibco BRL, Grand Island, NY, USA)
and 5% (v/v) newborn calf serum (Gibco BRL) as described previ-
ously [9]. The cultures were maintained in 5% CO2/95% humidi¢ed air
at 37‡C.
2.3. Treatment with PrP(106^126)
PrP(106^126) was prepared as a 10 mg/ml stock in sterile water and
incubated at 37‡C for 72 h, and then the solution of PrP(106^126) was
diluted to the required concentration with serum-free DMEM con-
taining 2 WM insulin.
2.4. Circular dichroism analysis of synthetic prion peptide
For circular dichroism (CD) analysis, the prion peptide was dis-
solved in 20 mM Tris^HCl bu¡er (pH 7.4). The CD spectra were
baseline-corrected and smoothed by the algorithm provided by the
manufacturer, and they were recorded at room temperature in a Jasco
model J-720 spectropolarimeter (Jasco, Tokyo, Japan) with a cell path
length of 10 mm. Five scans each of duplicate samples were measured
and averaged. Ellipticity was calculated as mean residue ellipticity [a]
(degrees cm2 dmol31).
2.5. Lactate dehydrogenase and WST-8 assay
The PC12 cells were seeded at 1U104 cells/well in 96-well plates
coated with type I collagen (Becton Dickinson Labware, Bedford,
MA, USA) at least 24 h before the experiment and cultured in se-
rum-free DMEM supplemented with 2 WM insulin. PrP(106^126) was
added to the cultures with or without stimulants, and the extent of cell
death was assessed by measurement of the activity of lactate dehydro-
genase (LDH) released from the dead cells. The LDH activity in the
culture medium was determined using a commercially available kit
(Wako, Osaka, Japan) according to the manufacturer’s protocol. In
addition to the LDH measurement in the medium, cell mortality was
also assayed by WST-8 conversion [12]. A volume of 10 Wl of WST-8
(5 mM WST-8, 0.2 mM 1-methoxy-5-methylphenazinium methylsul-
fate, and 150 mM NaCl) was added to each well and the incubation
was carried out for 4 h at 37‡C. The absorbance of the sample at 450
nm was measured using a microplate reader (Bio-Tek, Winooski, VT,
USA) with a reference wavelength of 720 nm.
2.6. Caspase-3-like activity
The caspase-3-like activity in culture was measured with the use of
an Apo-ONE1 Homogeneous Caspase-3/7 Assay Kit (Promega) ac-
cording to the manufacturer’s instructions. Brie£y, the cells (5U104
cells/well) in type I collagen-coated 96-well plates (Becton Dickinson
Labware) were rinsed twice with phosphate-bu¡ered saline (PBS). The
cultures were incubated with or without the indicated stimulants in
DMEM (50 Wl) at 37‡C in an atmosphere of 95% air and 5% CO2.
The cells were lysed in 50 Wl of Homogeneous Caspase-3/7 Bu¡er
containing the caspase-3 substrate Z-DEVD-rhodamine 110, and the
cell lysates were incubated for 12 h at room temperature. After in-
cubation, the cell lysates (50 Wl) were diluted with 2 ml of PBS, and
the £uorescence (excitation at 480 nm and emission at 535 nm) was
measured with an RF-5000 spectro£uorophotometer (Shimadzu, To-
kyo, Japan).
2.7. Statistical analysis
For statistical comparisons, one-way analysis of variance with pair-
wise comparison by the Fisher’s least signi¢cant di¡erence procedure
was used. A P value of less than 0.05 was considered signi¢cant for all
analyses.
3. Results
3.1. The protective e¡ects of PACAP27 on PrP(106^126)-
induced neurocytotoxicity
CD spectral analysis of PrP(106^126), prepared at a con-
centration of 80 Wg/ml, showed a combination of random-coil
and L-sheet structures, and the aggregation properties of this
PrP(106^126) were con¢rmed in the polyacrylamide gel elec-
trophoresis analyses [13]. To achieve complete conformational
conversion into abnormal L-sheet-rich structures that have
propensities to ¢brillize, PrP(106^126) was aged in an aqueous
solution at a high concentration (s 10 mg/ml). It is well-es-
tablished that the CD spectrum of the random-coiled struc-
ture shows an intense negative band at 198 nm and a weak
positive band at 220 nm, and that of the L-sheet structure
indicates an intense positive band at 198 nm and a negative
extremal band at 218 nm [14]. According to this interpreta-
tion, our CD spectral analysis indicated that normal PrP(106^
126), which exhibited a mixture of abundant random-coil and
a few L-sheet structures, was converted to the L-sheet-rich
structure after aging in our conditions (Fig. 1A). Therefore,
aged PrP(106^126) was used as a toxic agent throughout this
investigation.
Chronic exposure of PC12 cells to PrP(106^126) resulted in
a concentration-dependent decrease of cell viability assayed by
WST-8, which indicated a reduction in the mitochondria of
living cells (Fig. 1B). PrP(106^126) also stimulated the gradual
release of cellular LDH into the culture medium (Fig. 1C),
indicating the loss of cell membrane integrity in both necrotic
and apoptotic cells. The increase in LDH release by PrP(106^
126) was evident at 48 h after the treatment, although the
control medium treatment led to a slight induction of the
release of LDH. PACAP27 is believed to act as a potent
neurotrophic factor in the nervous system. When PACAP27
(1039 M) was administered to PC12 cells with PrP(106^126), a
signi¢cant decrease of LDH release was observed. PACAP27
is well-known as a potent activator of adenylate cyclase [5],
and db-cAMP, a cell-permeable cAMP analogue, mimicked
the neuroprotective e¡ect of PACAP27. PACAP27 suppressed
PrP(106^126)-induced cell death at concentrations as low as
10315 M, and this cytoprotective e¡ect was diminished at 1037
M, providing a bell-shaped dose dependence (Fig. 1D). Incu-
bation of PC12 cells with VIP (1037 M) also attenuated the
cytotoxicity of PrP(106^126), and these dose^response fash-
ions were consistent with our previous data of the PACAP27-
evoked activation of adenylate cyclase [15]. The present study
revealed that PACAP27 was 104-fold higher than VIP in neu-
roprotection against PrP(106^126) cytotoxicity. In addition,
PACAP was much higher than VIP in activation of adenylate
cyclase, catecholamine secretion and neurite outgrowth in
PC12 cells [9,10]. These results, taken together with the pre-
vious results showing the predominant expression of PAC1
receptor in PC12 cells [10], indicated that the e¡ect of PA-
CAP/VIP is mediated through the activation of ‘PACAP-pre-
ferring’ PAC1 receptors in PC12 cells. Hence, this is the rea-
son why PACAP27 at an extremely low concentration shows
signi¢cant biological activities.
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3.2. Signaling pathways involved in the neuroprotective e¡ect of
PACAP27
PACAP stimulates various protein kinases, including the
adenylate cyclase/protein kinase A (PKA), the phospholipase
C/protein kinase C (PKC) and the mitogen-activated protein
(MAP) kinase pathways [7]. PACAP exerts its neuronal ac-
tions through the activation of these kinases in the nervous
system. In order to clarify the possible signaling pathway in-
volved in the neuroprotective e¡ect of PACAP27, the e¡ect of
stimulators/inhibitors of protein kinases were examined. db-
cAMP, a potent PKA stimulator [16], showed a dose-depen-
dent neuroprotection against the toxicity of PrP(106^126)
(5U1035 M) (Fig. 2A). db-cAMP at the concentration of
1034 M resulted in a 120% survival of PC12 cells, probably
re£ecting defense against naturally occurring cell death in this
system. A potent PKC activator, TPA (1037 M) [17], reduced
the cytotoxicity of PrP(106^126), whereas TPA at higher con-
centrations (s 1036 M) showed no neuroprotection due to the
cytotoxicity itself (Fig. 2A). Next, when the selective PKA
inhibitor, N-(2-[p-bromocinnamylamino]ethyl)-5-isoquinoline-
sulfonamide (H89), was added simultaneously with PrP(106^
126) and PACAP27 (1039 M), the protective e¡ect of PA-
CAP27 against PrP(106^126)-induced neurotoxicity was in-
hibited signi¢cantly. U0126, a speci¢c MAP kinase inhibitor
[18], caused a marked attenuation of the PACAP27-evoked
neuroprotection. On the other hand, the selective PKC inhib-
itor, Myr-iPKC (1036 M) [19], showed no response against
the e¡ect of PACAP27 in this manipulation. Hence, the neu-
roprotection of PACAP27 was mediated through PKA and
MAP kinase, but not through PKC signaling pathways.
3.3. E¡ect of PACAP27 on caspase-3-like activity
Since the activation of caspase-3 is involved in neuronal
death during nervous system development and under certain
pathological conditions [20], we examined the caspase-3-like
activity in PC12 cells by measuring the ability of cell lysates to
cleave a £uorometric caspase-3 substrate, Z-DEVD-Rho-
damine 110 [21]. Cellular extracts from untreated control cul-
Fig. 1. PrP(106^126)-induced cytotoxicity and the e¡ects of neuropeptides on the cell viability in PC12 cells. A: Representative CD spectra of
the prion peptide in 20 mM Tris^HCl (pH 7.4). Solid line, normal PrP(106^126); dashed line, aged PrP(106^126). B: Dose-dependent neurotox-
icity of PrP(106^126) measured by WST-8 assay 72 h after chronic exposure of PC12 cells. Each bar represents the meansSS.D. of four experi-
ments. ##P6 0.01 with respect to control (vehicle alone). C: PC12 cells were treated with PrP(106^126) (5U1035 M) for 72 h along with dibu-
tyryl-cAMP (1034 M) or synthetic PACAP27 (1039 M), and the medium was assayed by the release of LDH every 24 h. E, control (vehicle
alone); F, PrP(106^126)-treated,; b, PrP(106^126)-treated with PACAP27; R, PrP(106^126)-treated with dibutyryl-cAMP. The results are the
meansSS.D. of four experiments. ##P6 0.01 and #P6 0.05 with respect to the control group. D: Dose-response curves (1031731037 M) of
PACAP27 (b) or VIP (R) on PrP(106^126) (5U1035 M)-treated PC12 cells. After 72-h incubation, the cell viability was assessed by measuring
the reduction of WST-8, and each value is the meansSS.D. of four experiments. ##P6 0.01 with respect to the PrP(106^126)-treated group
(without neuropeptides).
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tures showed a slight cleavage, while the activity of the Z-
DEVD-rhodamine 110 cleavage was elevated after treatment
with 5U1035 M PrP(106^126) (data not shown). This signi¢-
cant elevation in caspase-3-like activity was blocked by cas-
pase inhibitors, including Ac-DEVD-CHO, a caspase-3-specif-
ic inhibitor [22], and Z-VAD-FMK, an irreversible inhibitor
of several members of the caspase family [23] (data not
shown). The activation of caspase-3 reached the maximal level
at 12 h, and this elevated caspase-3 activity decreased gradu-
ally to the same level as control at 48 h (Fig. 3A). At 12 h
incubation, PACAP27, at the concentrations between 10313
and 1037 M, signi¢cantly deactivated the PrP(106^126)-
evoked caspase-3 activity up to 60% inhibition, producing a
dose-dependent curve (Fig. 3B). db-cAMP (1034 M) mim-
icked this e¡ect of PACAP27 (data not shown). Although
these data suggested the involvement of deactivation of cas-
pase-3 in the neuroprotective e¡ect of PACAP27, the addition
of Ac-DEVD-CHO resulted in partial inhibition (26%) of the
PrP(106^126)-induced cell death (Fig. 3C). Z-VAD-FMK
(1034 M) prevented cell death up to 77% inhibition after treat-
ment with PrP(106^126) (5U1035 M). These ¢ndings indi-
cated that at least caspase-3 was involved in the PrP(106^
126)-induced neuronal apoptosis, but other signaling path-
ways may be linked to the neuroprotection of PACAP27.
4. Discussion
Prion diseases are associated with conformational changes
of the prion protein into an abnormal L-sheet-rich structure,
which often has a tendency to accumulate as amyloid. The
structure of PrP(106^126) is also variable depending on the
conditions used [13]. Here, we demonstrated the marked con-
version of PrP(106^126) into the L-sheet-rich structure by
aging at a high concentration, which showed neurotoxicity
in neuron-like PC12 cells. In addition, we demonstrated the
neuroprotective e¡ect of PACAP27 on PrP(106^126)-induced
neuronal cell death. The neuroprotection of PACAP27 was
signi¢cantly e¡ective at extremely low concentrations
(10315 M). The PACAP-related neuropeptide, VIP, also
showed a similar neuroprotective e¡ect only at the higher con-
centrations (s 1039 M). PACAP/VIP are known to activate
adenylate cyclase, leading to increased levels of cAMP. With
respect to the e¡ect of PACAP/VIP on cAMP production in
PC12 cells, these two neuropeptides showed similar dose-re-
sponse curves in terms of the neuroprotective e¡ect, suggesting
that they exerted their neuronal action through cAMP pro-
duction [15]. In our investigation, db-cAMP (1034 M) mim-
icked the e¡ect of PACAP27 (1039 M), and the PKA inhib-
itor, H89, prevented the neuroprotective e¡ect of PACAP27.
In addition to the PKA signaling pathway, MAP kinase is a
key regulatory enzyme in the ¢nal common signaling pathway
for PACAP27-induced cellular proliferation, di¡erentiation
and neuroprotection in PC12 cells, and this kinase is activated
by PKA followed by the activation of adenylate cyclase [24].
We showed that the MAP kinase inhibitor, U0126, attenuated
the PACAP-evoked neuroprotection in PC12 cells. Hence, the
activation of MAP kinase by PKA is likely to be involved in
the signaling pathways for the neuroprotective e¡ect of PA-
CAP27 against PrP(106^126)-induced cytotoxicity.
There are at least three speci¢c receptors for PACAP/VIP,
such as PAC1 for PACAP, VPAC1 for VIP, and VPAC2 for
helodermin [7]. PACAP27 and VIP display similar a⁄nities
for VPAC1 and 2 receptors, whereas the binding activity of
PACAP toward PAC1 receptors is 1033104-fold higher than
VIP. With respect to the expression of PACAP/VIP receptors
in PC12 cells, an RT-PCR experiment clearly indicated the
dominant expression of the PAC1 receptor [10]. This result
was consistent with the present data showing that PACAP27
was more potent than VIP in the stimulation of adenylate
cyclase and the neuroprotection against the cytotoxicity of
PrP(106^126) in PC12 cells. As well as the activation of ade-
nylate cyclase, PACAP27 stimulates the accumulation of in-
tracellular calcium mediated via the PAC1 receptor, resulting
in the increase of inositol phosphates in neuronal cells [7]. We
demonstrated that low concentrations of TPA, a PKC activa-
tor, provoked the inhibition of PrP(106^126)-induced cell
death. On the contrary, Myr-iPKC, a potent PKC inhibitor,
Fig. 2. Involvement of protein kinase cascades in the neuroprotec-
tive e¡ect of PACAP27. A: E¡ect of PKA/PKC activator on
PrP(106^126)-induced cell death in PC12 cells. The cells were cul-
tured for 72 h with PrP(106^126) (5U1035 M) in the presence or
absence of db-cAMP (b) or TPA (R) at a ¢nal concentration be-
tween 1038 and 1034 M. The cell viability was assessed by the re-
duction of WST-8. The data represent the meansSS.D. of four ex-
periments. ##P6 0.01 with respect to the control group. B: E¡ects
of the selective protein kinase inhibitors on PACAP27-evoked neu-
roprotection. PC12 cells were treated with PrP(106^126) (5U1035
M) and PACAP27 (1039 M) in the absence or presence of the pro-
tein kinase inhibitors (1036 M) for 72 h, and the cell viability was
assessed by WST-8 reduction analysis. The data represent the
meansSS.D. of four experiments. ##P6 0.01 with respect to the
control group. **P6 0.01 and *P6 0.05 between PACAP27-treated
group with and without protein kinase inhibitor.
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failed to suppress the e¡ect of PACAP27 against the cytotox-
icity of the PrP fragment. These data suggested that the e¡ect
of PACAP27 on PrP(106^126)-induced cell death in PC12
cells is mediated through the PAC1 receptor, followed by
activation of the PKA and MAP kinase signaling pathways,
but not through the PKC signaling pathway.
Apoptosis is a physiologically important cellular suicide
pathway, and there is some evidence to indicate that the
mechanism of neuronal cell death in prion disease is apopto-
sis, as apoptotic neurons have been observed in the brain of
scrapie-infected sheep [25]. Apoptosis is mediated by the fam-
ily of cysteine, aspartyl-speci¢c proteases known as caspases,
and the activation of caspase-3 is required for DNA fragmen-
tation and morphological changes associated with apoptosis
[20]. In this study, PrP(106^126) activated the basal caspase-3-
like activity up to 155% at 12 h after PrP(106^126) challenge,
and then this elevated activity decreased gradually to the same
level as the control at 48 h. LDH release from PrP(106^126)-
treated PC12 cells occurred after 48-h incubation. This result
indicated that caspase-3 is activated prior to the loss of mem-
brane integrity. The addition of PACAP27 (s 10313 M) re-
sulted in a signi¢cant decrease of catalytic activity of caspase-
3, suggesting that PACAP27 acted as an anti-apoptotic agent
through the deactivation of caspase-3. A caspase-3-speci¢c
inhibitor slightly deactivated the caspase-3 in PrP(106^126)-
stimulated PC12 cells to increase the cell viability, while the
broad-spectrum caspase inhibitor, Z-VAD-FMK, showed
both clear prevention of caspase-activation and cell death.
Other groups have also reported that the inhibition of cas-
pase-3 was insu⁄cient to prevent PrP(106^126)-induced neu-
ronal cell death [26]. Taken together, these results suggest that
there is activation of critical cytotoxic factors upstream of
caspase activation, and that PACAP27 inhibits the neurotox-
icity of PrP(106^126) through caspase-3-dependent and inde-
pendent pathways.
In conclusion, the present study demonstrated, for the ¢rst
time, that PACAP27 acts as a neuroprotective agent against
PrP(106^126)-induced cell death. PACAP27 activates both the
PKA and MAP kinase signaling pathways through the PAC1
receptor, which may lead to the rescue of apoptotic cell death
induced by PrP as well as ischemia [27], glutamate [8], or
L-amyloid [15].
Fig. 3. E¡ects of PACAP27 on PrP(106^126)-evoked caspase-3 activity. A: PC12 cells were treated with PrP(106^126) (5U1035 M) and lysed
at the indicated period. Caspase-3-like activity in the cell lysate was determined £uorometrically using Z-DEVD-Rhodamine 110. The data are
expressed as percentage of the control value (meansSS.D. of four experiments). **P6 0.01 with respect to the control group. B: E¡ect of
graded concentration of PACAP27 on PrP(106^126)-stimulated caspase-3-like activity. PC12 cells were exposed for 12 h to PrP(106^126)
(5U1035 M) and PACAP27 at the indicated concentration, followed by measurement of the caspase-3-like activity. Each value is the
meansSS.D. of four experiments. **P6 0.01 with respect to the PrP(106^126)-treated group. C: E¡ects of caspase inhibitors on cell viability
in PrP(106^126)-treated cultures. PC12 cells were treated with PrP(106^126) (5U1035 M) for 72 h with or without the caspase inhibitors Ac-
DEVD-CHO (1034 M) or Z-VAD-FMK (1034 M). The cell viability was assessed by WST-8 reduction analysis, and each bar represents the
meansSS.D. of four experiments. **P6 0.01 and *P6 0.05 with respect to the PrP(106^126)-treated group.
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